公开(公告)号：US20240065995A1

公开(公告)日：2024-02-29

申请号：US18351359

申请日：2023-07-12

申请人： Darren Alexander Rubin

发明人： Darren Alexander Rubin

IPC分类号： A61K31/198 ,  A61K9/00 ,  A61K47/18

CPC分类号： A61K31/198 ,  A61K9/0019 ,  A61K47/183

摘要： Methods, formulations, and applications of increasing intracellular glutathione levels with at least one injectable cell membrane permeable prodrug or derivative of cysteine, glutamylcysteine, glutathione, or a combination thereof, to treat, reduce, or prevent cellular and tissue oxidative damage, to increase levels of amino acids, and to treat numerous disease states and conditions including inborn errors of metabolism, nutritional malabsorption, and aging.

公开(公告)号：US11913077B2

公开(公告)日：2024-02-27

申请号：US16979364

申请日：2019-03-09

申请人： Texas Tech University System

发明人： Charles Patrick Reynolds ,  Balakrishna Koneru ,  Shawn Macha

IPC分类号： C12Q1/6886 ,  A61K31/198 ,  A61K31/439 ,  A61K45/06 ,  A61P35/00

CPC分类号： C12Q1/6886 ,  A61K31/198 ,  A61K31/439 ,  A61K45/06 ,  A61P35/00 ,  C12Q2600/156

摘要： A method of treating a cancer in a patient includes obtaining a sample from the patient, using a C-circle assay to detect a presence of an alternative lengthening of telomeres (ALT) phenotype in the sample, and administering an effect amount of at least one of PRIMA-1 or APR-246 to the patient.

公开(公告)号：US11903935B2

公开(公告)日：2024-02-20

申请号：US17508321

申请日：2021-10-22

申请人： Washington University ,  Disarm Therapeutics, Inc.

发明人： Jeffrey Milbrandt ,  Kow Essuman ,  Yo Sasaki ,  Aaron Diantonio ,  Xianrong Mao ,  Rajesh Devraj ,  Raul Eduardo Krauss ,  Robert Owen Hughes

IPC分类号： A61K31/4439 ,  A61K47/55 ,  A61K47/52 ,  A61P25/28 ,  A61K33/243 ,  A61K31/047 ,  A61K31/145 ,  A61K31/198 ,  A61K31/41 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/4535 ,  A61K31/566 ,  A61K31/7048 ,  A61K31/7084 ,  A61K33/245 ,  A61K33/28 ,  A61K33/30

CPC分类号： A61K31/4439 ,  A61K31/047 ,  A61K31/145 ,  A61K31/198 ,  A61K31/41 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/4535 ,  A61K31/566 ,  A61K31/7048 ,  A61K31/7084 ,  A61K33/243 ,  A61K33/245 ,  A61K33/28 ,  A61K33/30 ,  A61K47/52 ,  A61K47/55 ,  A61P25/28

摘要： The present disclosure provides compounds useful as inhibitors of SARM1 NADase activity, compositions thereof, and methods of using the same. The present disclosure provides compounds useful for treating a neurodegenerative or neurological disease or disorder, compositions thereof, and methods of using the same.

公开(公告)号：US20240041826A1

公开(公告)日：2024-02-08

申请号：US17818026

申请日：2022-08-08

申请人： Rory Powell Blake

发明人： Rory Powell Blake

IPC分类号： A61K31/401 ,  A61K31/198 ,  A23L33/175 ,  A23L2/52 ,  C12G3/04 ,  A23D9/007 ,  A23L33/00

CPC分类号： A61K31/401 ,  A61K31/198 ,  A23L33/175 ,  A23L2/52 ,  C12G3/04 ,  A23D9/007 ,  A23L33/40 ,  A23V2002/00

摘要： The human body's response to excessive gut bacterial growth is to deny the microbiome of two classes of amino acids. This halts exponential growth; however, the body is also denied their benefit. In the short term, prevention of explosive infection is accomplished. However, this triggers the necessity of removing the needed amino acids from bodily structure for the body to continue. This becomes the resulting long-term decline seen in human aging. This disclosure is methods to extend to the body the benefit of those missing classes of amino acids by providing them in a form less accessible to bacteria. The preferred embodiments claimed in this disclosure work in tandem to treat and to slow aging.

公开(公告)号：US20240041810A1

公开(公告)日：2024-02-08

申请号：US18180734

申请日：2023-03-08

申请人： AXCELLA HEALTH, INC.

发明人： Michael Hamill ,  Raffi Afeyan ,  Chung-Wei Lee ,  Harry Luithardt

IPC分类号： A61K31/198 ,  A61P1/16 ,  A61K9/14 ,  A23L33/175 ,  A23L33/18 ,  A61K38/05 ,  A61K38/06

CPC分类号： A61K31/198 ,  A61P1/16 ,  A61K9/14 ,  A23V2250/0634 ,  A23L33/18 ,  A61K38/05 ,  A61K38/06 ,  A23L33/175

摘要： This disclosure provides pharmaceutical compositions comprising amino acid entities and uses thereof. Methods for improving liver function and for treating liver diseases comprising administering an effective amount of the compositions to a subject in need thereof are also disclosed.

公开(公告)号：US11890305B2

公开(公告)日：2024-02-06

申请号：US17671959

申请日：2022-02-15

申请人： Ajibike Omosalewa Salako-Akande

发明人： Ajibike Omosalewa Salako-Akande

IPC分类号： A61K31/00 ,  A61K35/60 ,  A61P25/30 ,  A61K31/4415 ,  A61K33/08 ,  A61K33/10 ,  A61K31/07 ,  A61K31/375 ,  A61K31/59 ,  A61K31/355 ,  A61K31/122 ,  A61K31/51 ,  A61K31/525 ,  A61K31/455 ,  A61K31/519 ,  A61K31/4188 ,  A61K31/197 ,  A61K31/714 ,  A61K33/06 ,  A61K33/26 ,  A61K33/42 ,  A61K33/18 ,  A61K33/30 ,  A61K33/34 ,  A61K33/32 ,  A61K33/24 ,  A61K33/20 ,  A61K33/00 ,  A61K31/01 ,  A61K31/05 ,  A61K31/198

CPC分类号： A61K35/60 ,  A61K31/01 ,  A61K31/05 ,  A61K31/07 ,  A61K31/122 ,  A61K31/197 ,  A61K31/198 ,  A61K31/355 ,  A61K31/375 ,  A61K31/4188 ,  A61K31/4415 ,  A61K31/455 ,  A61K31/51 ,  A61K31/519 ,  A61K31/525 ,  A61K31/59 ,  A61K31/714 ,  A61K33/00 ,  A61K33/06 ,  A61K33/08 ,  A61K33/10 ,  A61K33/18 ,  A61K33/20 ,  A61K33/24 ,  A61K33/26 ,  A61K33/30 ,  A61K33/32 ,  A61K33/34 ,  A61K33/42 ,  A61P25/30

摘要： A composition and method for ameliorating drug-seeking behavior in drug addicts who have stopped using the addicted-to drug and who have reestablished non-addict physiological chemical balance.

公开(公告)号：US11890266B2

公开(公告)日：2024-02-06

申请号：US17103709

申请日：2020-11-24

申请人： University of Canberra

发明人： Regan Scott Ashby

IPC分类号： A61K31/198 ,  A61K31/375 ,  A61K45/06 ,  A61P27/10 ,  A61K9/00

CPC分类号： A61K31/198 ,  A61K9/0019 ,  A61K9/0048 ,  A61K31/375 ,  A61K45/06 ,  A61P27/10 ,  A61K31/198 ,  A61K2300/00 ,  A61K31/375 ,  A61K2300/00

摘要： Pharmaceutical ocular compositions include levodopa, an antioxidant and an aqueous carrier. A wide selection of antioxidants can be included in the compositions, such as ascorbic acid, phenolic acids, sorbic acid, sodium bisulfite, sodium metabisulfite, acetyl cysteine, sodium thiosulfate, ethylene diamine tetraacetic acid, sodium nitrite, ascorbyl stearate, ascorbyl palmitate, alpha-thioglycerol, erythorbic acid, cysteine hydrochloride, citric acid, tocopherol or vitamin E, tocopherol acetate, dibutylhydroxytoluene, soybean lecithin, sodium thioglycolate, butylhydroxyanisole, propyl gallate, uric acid, melatonin, and thiourea, as well as salts and combinations of these antioxidants.

公开(公告)号：US20240033240A1

公开(公告)日：2024-02-01

申请号：US18479393

申请日：2023-10-02

申请人： UNIVERSITY OF SOUTH CAROLINA

发明人： Peisheng Xu ,  Eleni Markoutsa

IPC分类号： A61K31/198 ,  A61K47/69 ,  A61K47/54 ,  A61K47/55

CPC分类号： A61K31/198 ,  A61K47/6933 ,  A61K47/6935 ,  A61K47/54 ,  A61K47/55

摘要： The preparation of dual functionalized nanoparticles is generally provided along with their application. The dual functionalized nanoparticles provide dual targeting and can effectively pass the blood brain barrier and target brain tissue. The dual targeted and dual responsive nanoparticles are functionalized to include at least two different ligands that are capable of transport across the blood brain barrier. The nanoparticles can be prepared from polymeric materials that can be biocompatible, provide long circulation life in a body, and be successfully ligated to both functionalities by use of acid-sensitive and/or redox potential-sensitive bonds for delivery across the blood brain barrier and delivery of a payload to brain tissue.

公开(公告)号：US20240009162A1

公开(公告)日：2024-01-11

申请号：US18367876

申请日：2023-09-13

申请人： Todd Ewing

发明人： Todd Ewing

IPC分类号： A61K31/385 ,  A61K31/198

CPC分类号： A61K31/385 ,  A61K31/198

摘要： Provided are methods for enhancing cellular metabolism and cellular repair in a tissue of a subject in need thereof. The method includes administering a dose of at least an N-methyl-D-aspartate receptor glycine site agonist, an N-methyl-D-aspartate receptor REDOX site agonist, and a nuclear factor erythroid 2-related receptor agonist; wherein the dose induces cellular metabolic fitness activation in the subject. The method for enhancing cellular metabolism and cellular repair synergistically modulates a positive-feedback signal-amplification cycle comprising NMDAR and NRF2 in cells, which, in turn, promotes cellular metabolic fitness (CMF) in a tissue of a subject in need thereof.

公开(公告)号：US11865095B2

公开(公告)日：2024-01-09

申请号：US17490492

申请日：2021-09-30

申请人： Aminex Therapeutics, Inc.

发明人： Mark R. Burns

IPC分类号： A61K31/13 ,  A61K31/381 ,  A61K31/341 ,  A61K31/18 ,  A61K31/132 ,  A61K31/131 ,  A61P35/00 ,  A61K31/198

CPC分类号： A61K31/198 ,  A61K31/13 ,  A61K31/131 ,  A61K31/132 ,  A61K31/18 ,  A61K31/341 ,  A61K31/381 ,  A61P35/00 ,  A61K31/198 ,  A61K2300/00 ,  A61K31/132 ,  A61K2300/00

摘要： Provided herein are combinations comprising difluoromethylornithine (DFMO), or an ionic form thereof, and a compound of the following structural formula:




or a protonated form thereof, wherein values for the variables (e.g., a, b, c, d, e, n, R1, R2, X) are described herein. The combinations can provide combination drug therapy in a single pharmaceutical dosage form, and be used, for example, for the treatment of cancer.